2013年4月12日讯 /--Genentech公司在美国癌症研究联合会（American Association for Cancer Research）的年度会议上公布了一种治疗癌症的免疫疗法药物研究的部分数据。这种名为PD-L1-targeting的免疫疗法研究目前只有30名患者志愿参加研究。

一名研究者表示这种疗法在研究中表现出对肺癌、肾癌等多种癌症都有抑制作用。Genentech公司目前正在对该项目进行深入研究。

详细英文报道：

Genentech has stepped into the spotlight at the annual meeting of the American Association for Cancer Research, armed with promising data from a small early-stage study of a new immunotherapy cancer drug.

The study for the PD-L1-targeting immunotherapy was small. Only 30 patients with a range of advanced cancers were selected to help establish a maximum tolerated dose--the study's primary objective. But reflecting Genentech's high status in the cancer drug development world and the bullish expectations for immunotherapy, MPDL320A--which is designed to remove one of the brakes on the immune system as it's trained to go after cancer--drew careful scrutiny at the meeting.

Significantly, investigators say they were able to deliver the full dose range without spurring signs of toxicity, helping establish that they can take a high dose forward into Phase II. But in another sign of the times, investigators also detailed evidence of efficacy, something more and more scientists are doing in Phase I. They said that responses have been "durable" and in at least two cases investigators saw signs of complete responses, with the patients continuing to do well without follow-up treatments.

"We saw clear evidence of anti-tumor activity in a broad range of diagnoses, including lung cancer, kidney cancer, colon cancer and gastric cancer," said Dr. Michael Gordon, according to Reuters' Bill Berkrot.

Genentech is hoping that its PD-L1 strategy will prove more effective than the PD-1 programs now in development. Bristol-Myers Squibb ($BMY), for example, has tapped its PD-1 drug nivolumab as one of the most promising in its late-stage pipeline.